Pfizer (PFE) is navigating a challenging landscape as it grapples with declining demand for COVID vaccines and impending patent cliffs that threaten revenue from key drugs. The stock has plummeted over 50% from its 2021 peak, yet it remains a viable long-term investment option. While competitors like Eli Lilly (LLY) capitalize on the GLP-1 weight-loss market, Pfizer is making strategic moves, including acquiring a promising weight-loss drug and partnering with a Chinese firm for a GLP-1 pill.
Despite current headwinds, Pfizer’s commitment to innovation and its strong dividend yield of 6.4% present an attractive opportunity for income-focused investors. The company aims to maintain its dividend amidst pressures, suggesting a focus on long-term stability and growth.
For market professionals, Pfizer’s current valuation may offer a compelling entry point, particularly for those willing to endure short-term volatility in anticipation of future growth as its R&D efforts come to fruition.
Source: fool.com